References
- Hughes T, Deininger M, Hochhaus A, Brandford S, Radich J, Kaeda J, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood 2006; 108: 28–37
- Rulcova J, Zmekova V, Zemanova Z, Klamova H, Moravcova J. The effect of total-ABL, GUS and B2M control genes on BCR-ABL monitoring by real-time RT-PCR. Leuk Res 2007; 31: 483–491
- Soverini S, Martinelli G, Colarossi S, Gnani A, Gastagnetti F, Rosti G, et al. Presence or the emergence of a F317L BCR-ABL mutation may be associated with resistance to dasatinib in Philadelphia chomosome-positive leukemia. J Clin Oncol 2006; 24: e51–e52
- Khorashad J S, Milojkovic D, Mehta P, Anand M, Ghorashian S, Reid A G, et al. In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. Blood 2008; 111: 2378–2381
- Kantarjian H, Schiffer Ch, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood 2008; 111: 1774–1780
- Ernst T, Erben P, Müller M C, Paschka P, Schenk T, Hoffman J, et al. Dynamics of BCR-ABL mutated clones prior to hematologic or cytogenetic resistance to imatinib. Haematologica 2008; 93: 186–192
- Baccarani M, Saglio G, Goldman J, Hochaus A, Simonsson B, Appelbaum F, et al. Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet. Blood 2006; 108: 1809–1820